Volunteers meeting eligibility criteria will receive 3 weekly interdermal injections of the experimental AlloStim™ drug in the shoulder or buttocks muscle.  After this priming phase, subjects will undergo percutaneous cryoablation under CT image guidance followed by an intratumoral injection of AlloStim™ into the ablated lesion.  After this vaccination phase, subjects will receive an intravenous AlloStim™ infusion.  The baseline amount of tumor burden and Th1/Th2 immune status will be evaluated and compared to evaluation at 30 days and 90 days.